BioSight

Company Overview

Snapshot

Founded in November 1999 by Stela Gengrinovitch, PhD and Mark Gengrinovitch, BioSight operates with 1–10 employees. The company raised a total of $62.5M across 5 funding rounds from 9 investors. In October 2023, BioSight was acquired by Ayala Pharmaceuticals.

Business overview

BioSight is a clinical-stage biotechnology company focused on developing therapeutics for hematological malignancies and disorders. Its core product, BST-236 (aspacytarabine), is a proprietary anti-metabolite designed for high-dose therapy with reduced systemic toxicity. The company serves the pharmaceutical and healthcare industries, specifically targeting oncology and hematology markets with its drug discovery and biopharmaceutical solutions.

Strategic signal

In November 2022, BioSight initiated a Phase 1/2 clinical trial for aspacytarabine in combination with venetoclax for first-line acute myeloid leukemia (AML) induction therapy, followed by aspacytarabine consolidation. This development signals the company's continued commitment to advancing its lead product and exploring new treatment regimens, potentially expanding its market reach and therapeutic impact in AML.

Company Intelligence Q&A

What was BioSight's most recent significant corporate event?

BioSight was acquired by Ayala Pharmaceuticals in October 2023, leading to its current inactive status.

When did BioSight last raise funding and from whom?

In December 2020, BioSight closed a Series C financing round. Israel Biotech Fund led the round, with participation from Arkin Bio.

What is BST-236 and its current clinical development status?

BST-236 (aspacytarabine) is BioSight's lead anti-metabolite product, designed to enable high-dose therapy with reduced systemic toxicity. In November 2022, a Phase 1/2 clinical trial was launched to investigate BST-236 in combination with venetoclax for first-line AML induction therapy.

Has BioSight received any special designations for its lead product?

Yes, in August 2020, BioSight was granted U.S. FDA Fast Track Designation for BST-236 for the treatment of Acute Myeloid Leukemia. Previously, in June 2019, the company received Orphan Drug Designation from the FDA for BST-236 for the same indication.

When did BioSight secure its earlier Series C funding?

In March 2020, BioSight secured Series C funding. Israel Biotech Fund led this round, with participation from Arkin Bio.